Aktis Oncology, Inc. Common stock (AKTS) is a publicly traded the market company. As of May 21, 2026, AKTS trades at $19.04 with a market cap of $1.03B and a P/E ratio of -9.99. AKTS moved +3.03% today. Year to date, AKTS is +24873.80%; over the trailing twelve months it is flat. Its 52-week range spans $0.03 to $29.16. Analyst consensus is strong buy with an average price target of $33.50. Rallies surfaces AKTS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies organizes AKTS SEC filing research, company disclosures, 10-K reports, 10-Q reports, and filing-driven context alongside market data, news, fundamentals, and AI research.
| Metric | Value |
|---|---|
| Price | $19.04 |
| Market Cap | $1.03B |
| P/E Ratio | -9.99 |
| EPS | $-1.89 |
| Dividend Yield | 0.00% |
| 52-Week High | $29.16 |
| 52-Week Low | $0.03 |
| Volume | 200 |
| Avg Volume | 0 |
| Revenue (TTM) | $27.38M |
| Net Income | $-167.95M |
| Gross Margin | -2.52% |
4 analysts cover AKTS: 0 strong buy, 4 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $33.50.